-+ 0.00%
-+ 0.00%
-+ 0.00%

On November 17, Cinda Biopharmaceuticals Group announced that Takeda Pharmaceuticals has been granted Tankan atotamab SAKIGAKE certification by the Ministry of Health, Labor, and Welfare of Japan. The proposed indication is CLDN 18.2 positive, unresectable, advanced or recurrent gastric or gastroesophageal junction adenocarcinoma (G/GEJA) that progresses after chemotherapy.

Zhitongcaijing·11/17/2026 07:34:06
Listen to the news
On November 17, Cinda Biopharmaceuticals Group announced that Takeda Pharmaceuticals has been granted Tankan atotamab SAKIGAKE certification by the Ministry of Health, Labor, and Welfare of Japan. The proposed indication is CLDN 18.2 positive, unresectable, advanced or recurrent gastric or gastroesophageal junction adenocarcinoma (G/GEJA) that progresses after chemotherapy.